Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
Rhea-AI Summary
Haemonetics (NYSE: HAE) will release third quarter fiscal 2026 results at 6:00 am ET on Thursday, February 5, 2026. The company will host a conference call with investors and analysts at 8:00 am ET on February 5, 2026, accessible by teleconference after registration, which provides a dial-in number and personalized PIN. A live webcast will be available on Haemonetics' investor relations website at the provided link. A replay of the conference call and webcast will be available for one year starting February 5, 2026 at 11:00 am ET. Participants are recommended to join the call 10 minutes early.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – HAE
On the day this news was published, HAE gained 1.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 02 | Conference appearance | Neutral | -0.2% | Announcement of CEO presentation at J.P. Morgan Healthcare Conference. |
| Nov 06 | Earnings release | Positive | +32.3% | Second quarter fiscal 2026 results and materials posted to IR site. |
| Oct 09 | Earnings date set | Neutral | -2.6% | Scheduled Q2 FY26 results date and associated conference call details. |
| Aug 07 | Earnings release | Negative | -26.6% | First quarter fiscal 2026 financial results posted and discussed with investors. |
| Jul 09 | Earnings date set | Neutral | +0.8% | Scheduled Q1 FY26 results release and follow-up conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings result releases for fiscal 2026 have triggered large price swings, while simple earnings date announcements and conference appearances have produced relatively modest moves, generally aligning with the informational nature of each event.
Over the last six months, Haemonetics has repeatedly guided investors to upcoming results and then posted detailed earnings via its Investor Relations site. First and second quarter fiscal 2026 earnings releases on Aug 7, 2025 and Nov 6, 2025 drove large moves of -26.58% and +32.31%, respectively, underscoring the market’s sensitivity to fundamentals. By contrast, prior earnings date notices on Jul 09, 2025 and Oct 09, 2025 and the Jan 13, 2026 JPM conference appearance saw comparatively small reactions, similar in nature to today’s scheduling update for the Q3 FY26 release.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/uz42wd2z
A replay of the conference call and webcast will be available for one year beginning on February 5, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-third-quarter-fiscal-year-2026-results-february-5-2026-302655773.html
SOURCE Haemonetics Corporation